Izac J. Findlay
New Lambton Heights, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Correction to: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.
Journal: Clinical proteomics
Published: April 08, 2023
Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies.
Journal: Science signaling
Published: March 28, 2023
ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
Journal: Cancer research
Published: March 22, 2023
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Journal: Cancer research
Published: March 22, 2023
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
Journal: The Journal of clinical investigation
Published: March 08, 2023
Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.
Journal: Clinical proteomics
Published: October 10, 2022
B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.
Journal: Molecular cancer research : MCR
Published: July 18, 2022
Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.
Journal: Neuro-oncology advances
Published: January 06, 2022
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.
Journal: Nature genetics
Published: October 28, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026